Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Marizomib + Pomalidomide + Dexamethasone in RRMM
NCT02103335Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Jun 2014
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of marizomib in multiple myeloma (MM), sponsored by Celgene Corporation. Primary endpoint: Maximum Tolerated Dose and/or Recommended Phase 2 Dose at 1 year. Started Jun 2014; status: completed.
02
Drugs
marizomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02103335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02103335.